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Abstract 25 
Pharmacokinetic (PK) data describing a prolonged time-course of antiretrovirals in plasma 26 
and peripheral blood mononuclear cells (PBMCs) are important for understanding and 27 
management of late or missed doses and to assess appropriateness of compounds for pre-28 
exposure prophylaxis (PrEP). This study aimed to evaluate the PK of coformulated tenofovir 29 
DF, emtricitabine and rilpivirine in plasma and intracellular (IC) anabolites, tenofovir 30 
diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in healthy volunteers up to 9 31 
days after drug cessation. Individuals received daily tenofovir DF/emtricitabine/rilpivirine 32 
(245/200/25 mg) for 14 days. Drug intake was stopped and serial sampling occurred prior to 33 
the final dose and up to 216 hours (9 days) after stopping drug. Concentrations were 34 
quantified and PK parameters calculated. Eighteen volunteers completed the study. 35 
Geometric mean (90% CI) tenofovir and emtricitabine terminal elimination plasma half-life 36 
within 216 hours was longer than 0-24 hours [tenofovir: 31 (27-40) vs. 13.3 (12.5-15.1) 37 
hours; emtricitabine: 41 (36-54) vs. 6.4 (5.9-7.6) hours]. Model-predicted IC half-lives (0-38 
168) were 116 (TFV-DP) and 37 hours (FTC-TP). Plasma rilpivirine at 216 hours was 4.5 39 
ng/mL (4.2-6.2) and half-lives 0-216 and 0-24 were 47 (41-59) and 35 (28-46) hours, 40 
respectively. These data contribute to our understanding of drug behaviour following 41 
treatment interruption however adherence to therapy should be promoted. Validated plasma 42 
and IC target concentrations are necessary to allow interpretation with respect to sustained 43 
virus suppression or HIV prevention.  44 
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Introduction 45 
The challenge of maintaining a high level of adherence to antiretroviral therapy has been 46 
aided, in part, by the development of fixed dose combination tablets suitable for once daily 47 
dosing, such as Atripla® [tenofovir disoproxil fumarate (DF)/emtricitabine/efavirenz; Gilead 48 
Sciences Ltd, London, UK] and Eviplera® (or Complera®; tenofovir 49 
DF/emtricitabine/rilpivirine; Gilead Sciences Ltd, London, UK and Gilead Sciences Inc., 50 
Foster City, CA, USA). Eviplera®, containing  rilpivirine, a non-nucleoside reverse 51 
transcriptase inhibitor (NNRTI), and tenofovir DF and emtricitabine (a nucleotide and 52 
nucleoside reverse transcriptase inhibitor, respectively) is approved in Europe for treatment 53 
of HIV-infected adults without NNRTI-associated resistance mutations, or mutations 54 
associated with tenofovir or emtricitabine resistance, and viral loads ≤100,000 copies/mL (1). 55 
In the US it has been approved for therapy-naïve adults with viral load ≤100,000 copies/mL 56 
and for switching virologically suppressed patients (viral load <50 copies/mL) under certain 57 
conditions (2). Moreover, encouraging therapeutic outcomes and improved lipid profiles have 58 
been observed switching suppressed patients to tenofovir DF/emtricitabine/rilpivirine from 59 
tenofovir DF/emtricitabine/efavirenz or raltegravir-based regimens (3). 60 
 61 
Despite the inroads made into improving patient adherence to therapy, delays in drug intake 62 
or missed doses can occur as a result of individual circumstances e.g. busy lifestyle or 63 
personal problems, risking viral rebound and resistance emergence. Key pharmacokinetic 64 
(PK) characteristics such as a prolonged elimination half-life, are likely to be more forgiving 65 
of late or missed doses, however PK data under these conditions are lacking, particularly for 66 
coformulated regimens. Although patients are instructed to maintain a high level of 67 
adherence, information regarding drug persistence in plasma and cells following treatment 68 
interruption could potentially improve management of late or missed doses. 69 
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 70 
Data describing persistence of drugs within plasma, cells and other physiological 71 
compartments are also essential for HIV prevention strategies such as pre-exposure 72 
prophylaxis (PrEP), determining which drugs may have suitable PK properties. Coformulated 73 
tenofovir DF/emtricitabine (Truvada®; Gilead Sciences Ltd, London, UK) was approved by 74 
the US Food and Drug Administration in 2012 for use as PrEP in high risk individuals and 75 
those engaging in sexual activity with HIV-infected partners (4). An intramuscularly 76 
administered, long acting formulation of rilpivirine is also under investigation as a PrEP 77 
agent (5).  78 
 79 
Tenofovir (administered as tenofovir disoproxil fumarate and rapidly converted by esterases 80 
following absorption to tenofovir) and emtricitabine are prodrugs that require intracellular 81 
(IC) phosphorylation to their active anabolites. While tenofovir is a monophosphate analogue 82 
requiring two phosphorylation steps to tenofovir diphosphate (TFV-DP), emtricitabine 83 
triphosphate (FTC-TP) is formed by three endogenous enzymatic steps (6). Concentrations of 84 
parent compounds in plasma and of TFV-DP and FTC-TP within peripheral blood 85 
mononuclear cells (PMBC) have been reported in combination with efavirenz (Atripla®) over 86 
9.5 days after stopping therapy in healthy volunteers (7) however, their PK profiles 87 
coformulated with rilpivirine after stopping medication have not been evaluated. Moreover, 88 
rilpivirine plasma PK and terminal half-life after drug cessation has not been previously 89 
investigated. 90 
 91 
The primary aim of this study was to evaluate plasma PK of tenofovir, emtricitabine and 92 
rilpivirine and IC TFV-DP and FTC-TP PK in healthy, HIV negative volunteers over nine 93 
days following drug intake cessation. 94 
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 95 
Materials and Methods 96 
Study population 97 
Male or non-lactating, non-pregnant females aged 18 to 65 years with a body mass index 98 
(BMI) of 18-35 kg/m2 who provided written informed consent were eligible for enrolment. 99 
Exclusion criteria included the presence of any significant acute or chronic medical illness; a 100 
positive screen for hepatitis B, C or HIV; evidence of organ dysfunction or abnormal physical 101 
examination; abnormalities in vital signs, ECG or clinical laboratory parameters; current or 102 
recent (within three months) gastrointestinal disease; clinically relevant alcohol or drug use 103 
(including positive urine drug screen) or those considered by the Investigator to affect 104 
compliance with trial procedures; exposure to any investigational drug or placebo within 105 
three months of first dose of study drug; use of any other drugs including over-the-counter 106 
medications and herbal preparations within two weeks of the first dose of study drug; known 107 
allergy to any constituents of study drug; or females of childbearing potential not using 108 
effective non-hormonal birth control methods. 109 
 110 
Study design 111 
This was a 23 day (excluding screening and follow up), open-label, single-treatment arm, PK 112 
study, carried out at the PK Unit of St Stephen’s Centre, Chelsea & Westminster Foundation 113 
Trust (London, UK). The study was reviewed and approved by the National Research Ethics 114 
Service (NRES Chelsea, London) and trial conduct was in accordance with the Declaration of 115 
Helsinki (EudraCT 2012-002781-13). 116 
 117 
Routine laboratory tests were performed at screening and drug safety and tolerability were 118 
assessed throughout the study period according to the NIAID Division of AIDS (ACTG) 119 
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grading scale for adverse events (grade 1, mild - grade 4, life-threatening) in addition to 120 
monitoring of vital signs, physical examinations and clinical laboratory investigations. 121 
 122 
Following a 10 hour overnight fast on study day 1 (baseline visit), participants were 123 
administered tenofovir DF/emtricitabine/rilpivirine (245/200/25 mg) with a 533 kcal 124 
breakfast.  All participants continued tenofovir DF/emtricitabine/rilpivirine once daily at 125 
home and adherence was monitored by questionnaire and pill-count. On day 14, individuals 126 
were admitted to the research unit and blood collection for drug quantification commenced 127 
immediately before (within 10 minutes) the final tenofovir DF/emtricitabine/rilpivirine dose 128 
(pre-dose, 0 hours). Samples were drawn at 2, 4, 8 and 12 hours after stopping the drug. 129 
Subjects were discharged thereafter, returning to provide 24, 36, 48, 60, 72, 96, 120, 144, 130 
168, 192 and 216 hours samples. All visits to the unit included documentation of concomitant 131 
medications and adverse events. A final follow-up visit between days 30 and 36 reviewed 132 
adverse events, vital signs and clinical laboratory assessments.  133 
 134 
Analytical methods 135 
Plasma collection for tenofovir, emtricitabine and rilpivirine quantification 136 
Blood was collected into lithium heparin Vacutainer blood collection tubes which were 137 
immediately inverted several times, placed in a light-protective container, and kept on ice or 138 
refrigerated until centrifugation. Samples were centrifuged (10 minutes, 1200 g, 4°C) within 139 
30 minutes of collection and plasma stored in light-protective amber-coloured tubes (-20°C) 140 
prior to shipping on dry ice to the Good Clinical Laboratory Practice (GCLP)-accredited 141 
Liverpool Bioanalytical Facility (Liverpool, UK) for analysis. 142 
 143 
Peripheral blood mononuclear cell isolation for TFV-DP and FTC-TP quantification 144 
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PBMCs were obtained as previously described (7). There was a technical issue generating the 145 
cell counts which meant that IC TFV-DP and FTC-TP could not be determined by 146 
bioanalytical methods. 147 
 148 
Quantification of tenofovir and emtricitabine and rilpivirine in plasma 149 
Plasma tenofovir, emtricitabine and rilpivirine were determined using fully validated liquid 150 
chromatography-tandem mass spectrometry (LC-MS/MS) methods (7, 8). Lower limit of 151 
quantification (LLQ) was 0.5 ng/mL and assay precision was <15% for all three drugs. 152 
 153 
Modelling and prediction of TFV-DP and FTC-TP concentrations in peripheral blood 154 
mononuclear cells 155 
Modelling of plasma tenofovir and emtricitabine linked to their IC anabolites (TFV-DP, 156 
FTC-TP) has been previously described using various approaches (9-11). This methodology 157 
was explored to allow prediction of TFV-DP and FTC-TP, up to 168 hours (7 days) 158 
following drug cessation, from plasma data. 159 
 160 
Separate models were developed for tenofovir and emtricitabine using nonlinear mixed 161 
effects modelling (NONMEM v. 7.2, ICON Development Solutions, Ellicott City, MD, USA) 162 
(12), and initial parameter estimates for plasma data were taken from the literature (9, 13). 163 
 164 
Plasma tenofovir and emtricitabine and time-matched TFV-DP and FTC-TP concentrations 165 
from a previous study investigating tenofovir, emtricitabine and efavirenz PK (Atripla®) 166 
following drug cessation in healthy volunteers (EFV study) (7) were used as prior 167 
information to describe the relationship between plasma and IC anabolite concentrations. All 168 
data from both studies were modelled simultaneously. Plasma and IC concentrations between 169 
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0-156 hours (6.5 days) for the EFV study and plasma concentrations between 0-168 hours (7 170 
days) for the present study were included as this provided the majority of samples above 171 
assay LLQ. Samples <LLQ between 0-156 and 0-168 hours were excluded from the 172 
modelling process.  173 
 174 
The influence of covariates: age, weight, BMI, serum creatinine, creatinine clearance [CrCL; 175 
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 176 
formula (14)], sex, ethnicity and food intake (drug administration under fasted vs. fed 177 
conditions) on plasma tenofovir and emtricitabine PK were investigated. To accept a model 178 
with one extra parameter a decrease in the minimal objective function value (OFV) of at least 179 
3.84 units was required (p=0.05, χ2 distribution, 1 d.f.). A backwards elimination step was 180 
performed once significant covariates were included; biologically plausible covariates 181 
producing an increase in OFV (>6.64 units; p=0.01, χ2 distribution, 1 d.f.) upon removal 182 
were retained. 183 
 184 
To evaluate the models, 90% prediction intervals (P5-P95) using final parameter estimates 185 
were generated from 1000 simulated individuals with the same distribution of covariates as 186 
the original dataset and observed data were superimposed. At least 90% of observed data 187 
within the prediction interval was representative of an adequate model. 188 
 189 
Final model parameters were used to predict IC TFV-DP and FTC-TP concentration-time 190 
profiles for the present study between 0-168 hours. Plasma PK parameters were fixed to 191 
individual Bayesian estimates for the present study and population parameters obtained for 192 
the relationship between drug in plasma and IC anabolites were used as prior information. 193 
Predictions were made utilising the $SIMULATION option of NONMEM.  194 
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 195 
Statistical Analysis 196 
This was an exploratory study and no formal sample size calculation was performed. It was 197 
estimated that sixteen subjects completing the study would allow for relevant conclusions. 198 
 199 
Area under the concentration-time curve 0-24 hours post-dose (AUC0-24) and to the last 200 
measureable time point within 216 hours (AUC0-last), maximum concentration (Cmax) and 201 
concentration 24 hours post-dose (C24) were calculated for plasma tenofovir, emtricitabine 202 
and rilpivirine using non-compartmental methods (WinNonlin Phoenix v. 6.3, Pharsight 203 
Corporation, Mountain View, CA, USA). Terminal elimination half-life was determined to 204 
the last measureable time point within 216 hours. 205 
 206 
AUC0-24 and 0-168 (AUC0-168), Cmax and C24 were calculated as outlined above for TFV-DP 207 
and FTC-TP using model predicted concentrations. Terminal elimination half-life was 208 
calculated using the formula: ln(2)/k40 (k40: rate constant for loss or elimination of TFV-DP 209 
or FTC-TP; Fig. S1).   210 
 211 
Pharmacokinetic parameters were summarised as geometric mean (90% CI) and 212 
interindividual variability expressed as co-efficient of variation [CV%; (standard 213 
deviation/mean)*100]. 214 
 215 
Results 216 
Study population 217 
Eighteen participants (11 female; 61%) completed the study. Median (range) age, weight, 218 
BMI, serum creatinine and CrCL were 31 years (19-47), 75 kg (60-105), 24 kg/m2 (21-31), 219 
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73 μmol/L (57-104) and 103 ml/min/1.73 m2 (78-146), respectively. Participants described 220 
themselves as Caucasian (n=10), Black-Caribbean (n=2), Black-African (n=2), Asian (n=1), 221 
Hispanic (n=1) and mixed ethnicity (n=2). Study drug was well tolerated and no grade 3 or 4 222 
adverse events were reported.  223 
 224 
Plasma tenofovir, emtricitabine and rilpivirine pharmacokinetics 225 
Of 288 samples, 20 (7%; 120-216 hours), 5 (2%; 168-216 hours) and 1 (0.3%; 192 hours) 226 
were below the LLQ for tenofovir, emtricitabine and rilpivirine, respectively.  Nine, 15 and 227 
17 individuals had quantifiable tenofovir, emtricitabine and rilpivirine at all sampling time 228 
points between 0-216 hours after stopping drug. 229 
 230 
Geometric mean plasma concentrations over time for tenofovir, emtricitabine and rilpivirine 231 
are shown (Fig. 1) and PK parameters summarised (Table 1). Geometric mean (90% CI) 232 
terminal elimination half-life to the last measureable time-point within 216 hours was 233 
markedly longer than that of 0-24 hours for tenofovir and emtricitabine [30.7 h (27.2-39.7) 234 
vs. 13.3 h (12.5-15.1) and 40.5 h (35.8-53.5) vs. 6.44 h (5.88-7.55)]. Elimination half-life 0-235 
216 was slightly longer than 0-24 for rilpivirine [47.2 h (41.3-59.3) vs. 34.6 h (28.4-45.9)]. 236 
Rilpivirine geometric mean (90% CI) C216 was 4.53 ng/mL (4.22-6.15). A therapeutic cut-off 237 
has not been defined for rilpivirine but 50 ng/mL has been suggested based on unpublished 238 
data (5). At 24 and 36 hours (representing a 12 hour delayed dose), 2/18 (11%) and 6/18 239 
(33%) of participants had concentrations below 50 ng/mL; 7/18 (39%) and 11/18 (61%) were 240 
below this value 72 hours after stopping the drug.   241 
 242 
Prediction of intracellular tenofovir diphosphate and emtricitabine triphosphate 243 
concentrations 244 
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Sixteen healthy volunteers (5 female; n=11 Caucasian, n=2 Black-African, n=2 mixed 245 
ethnicity, n=1 Asian) from the EFV study were included. Median (range) age, weight, BMI, 246 
serum creatinine and CrCL were 32 years (21-57), 81 kg (54-109), 27 kg/m2 (21-35), 81 247 
μmol/L (60-112) and 102 ml/min/1.73 m2 (72-126), respectively. Of 206 and 207 evaluable 248 
plasma and intracellular samples, the EFV study (7) contributed 203 and 206 plasma 249 
tenofovir and emtricitabine concentrations (<LLQ: n=3, n=0; respectively) and 183 and 207 250 
TFV-DP and FTC-TP concentrations (<LLQ: n=24, n=0, respectively). The present study 251 
contributed 245 (n=6 <LLQ) and 250 (n=1 <LLQ) plasma tenofovir and emtricitabine 252 
concentrations to the models. 253 
 254 
A diagrammatic summary of the model structure used for both drugs is shown (Fig. S1). 255 
Plasma tenofovir and emtricitabine were best described by a two-compartment oral model, 256 
parameterised by apparent oral clearance (CL/F), apparent volume of the central (Vc/F) and 257 
peripheral compartments (Vp/F), intercompartmental clearance (Q/F) and absorption rate 258 
constant (ka). Due to lack of information in absorption phase the ka of both drugs were fixed 259 
to literature values; 1.05 h-1 and 0.53 h-1 for tenofovir and emtricitabine, respectively (9, 13). 260 
Residual variability was described by a proportional error model and inclusion of 261 
interindividual variability (IIV) was supported on CL/F and Vp/F for tenofovir and CL/F, 262 
Vc/F and Vp/F for emtricitabine. TFV-DP and FTC-TP from the EFV study were described 263 
by first-order rate constants, k24 (uptake and conversion to phosphorylated form) and k40 (loss 264 
of anabolite). IIV was included on k24 and a proportional error model described residual 265 
variability. 266 
 267 
Inclusion of a food (or partner drug) effect on relative bioavailability (F1) for tenofovir but 268 
not emtricitabine significantly improved the fit. F1 was fixed to 1 (i.e. 100%) for the fasted 269 
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state (or with efavirenz) and increased by 33% with food (or with rilpivirine; Table S2). 270 
Inclusion of weight on clearance and volume parameters using allometric scaling 271 
significantly improved the tenofovir model as did addition of CrCL (linear function) on 272 
tenofovir CL/F. CrCL was significantly associated with emtricitabine CL/F (linear function). 273 
 274 
Population parameters from the final models are shown (Table S2). Diagnostic plots 275 
suggested that both models adequately described the data and was confirmed by the visual 276 
predictive checks with 90% and 92% of observed plasma tenofovir and TFV-DP 277 
concentrations, respectively within the 90% prediction interval and 92% and 94% of plasma 278 
emtricitabine and FTC-TP concentrations, respectively within the prediction interval (Figure 279 
S3).   280 
 281 
Intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics 282 
Geometric mean predicted TFV-DP and FTC-TP concentrations over 168 hours are 283 
illustrated (Fig. 2) and PK parameters shown (Table 1). Model-derived terminal elimination 284 
half-lives (0-168 hours) for TFV-DP and FTC-TP were 116 (4.8 days) and 37 hours (1.5 285 
days), respectively. 286 
 287 
IC TFV-DP and FTC-TP target concentrations for HIV suppression are not known, however 288 
HIV prevention targets have been determined using PK data from the iPrEx trial. Ninety 289 
percent risk reduction was associated with 16 fmol/106 and 3.7 pmol/106 viable cells for 290 
TFV-DP and FTC-TP, respectively (15).  At 24, 36, 48 and 72 hours after stopping drug 291 
predicted TFV-DP were <16 fmol/106 cells in 6%, 0%, 1% and 22% of individuals, 292 
respectively whilst 56%, 78%, 83% and 83%, respectively were below 3.7 pmol/106 cells for 293 
predicted FTC-TP.  294 
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Discussion 295 
Concentrations in plasma of tenofovir, emtricitabine, and for the first time rilpivirine, have 296 
been demonstrated over 9 days (216 hours) after stopping tenofovir 297 
DF/emtricitabine/rilpivirine intake in healthy, HIV-negative adults. Prediction of IC TFV-DP 298 
and FTC-TP concentrations from plasma data was also achieved utilising modelling and 299 
simulation and prior information from a previous, similar study (7). 300 
 301 
A therapeutic cut-off for sustained viral suppression has not been defined for rilpivirine, but 302 
50 ng/mL has been suggested based on an unpublished analysis of phase III trials in which 50 303 
ng/mL was the upper limit of the lowest quartile of trough concentrations in which 304 
virological response was lowest (5). Eleven percent, 33% and 39% of individuals had 305 
concentrations below this threshold value 24, 36 and 48 hours after stopping drug, 306 
respectively. However, these data should be interpreted with caution given that 50 ng/mL is 307 
not a validated target concentration. The long elimination half-lives of 35 hours (0-24) and 47 308 
hours (0-216) determined as part of this study are consistent with that previously reported for 309 
rilpivirine [45 hours (16, 17)]. The data presented indicate that rilpivirine exhibits PK 310 
properties that may allow forgiveness for delayed dosing in some patients however, 311 
individuals should be instructed to adhere to licensed dosing guidelines. 312 
 313 
Tenofovir plasma exposure was higher in the present study compared to that obtained by 314 
Jackson et al., in healthy volunteers stopping therapy [AUC0-last: 4249 vs. 2895 ng.h/mL (7)] 315 
and was highlighted during the modelling process. The two studies were conducted at the 316 
same research unit and bioanalysis occurred at the same laboratory. However, the NNRTI in 317 
the fixed dose combination was different between studies (efavirenz vs. rilpivirine) as were 318 
the food intake conditions. The EFV study was conducted under fasting conditions (2 hours 319 
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prior and after drug intake); however rilpivirine must be administered with food in order to 320 
achieve optimal absorption. Tenofovir exposure, as a component of tenofovir 321 
DF/emtricitabine/rilpivirine has been shown to increase by 38% following a standard meal 322 
(540 kcal) (1). A non-clinically relevant increase in plasma tenofovir of 24% has also been 323 
reported upon co-administration with rilpivirine, potentially through mild inhibition of the 324 
renal transmembrane transporters responsible for tenofovir renal elimination (18). However, 325 
an interaction has not been observed during co-administration with efavirenz (19). Inclusion 326 
of a food effect on F1 (relative bioavailability) improved the tenofovir model, resulting in a 327 
33% higher F1 for the present study compared to the EFV study. This could also be attributed 328 
to the interaction with rilpivirine or a combination of both a food and partner drug effect. 329 
Emtricitabine PK parameters were within the ranges previously reported and is known to be 330 
unaffected by food intake or co-administration with rilpivirine (1, 7). Terminal elimination 331 
half-lives to the last measureable time point within 216 hours for both nucleosides were 332 
considerably longer than over 0-24 hours (tenofovir: 31 vs. 13 hours; emtricitabine: 41 vs. 6 333 
hours) and were also in agreement with values from the earlier study (7). 334 
 335 
Due to issues with PBMC cell counts, TFV-DP and FTC-TP could not be directly quantified 336 
however a modelling approach was explored using the observed plasma tenofovir and 337 
emtricitabine concentrations and data from another study as prior information. The model 338 
was relatively simplistic using an effect compartment for TFV-DP or FTC-TP linked to the 339 
plasma compartment by a rate constant (k24) describing a number of processes including the 340 
uptake and metabolism of tenofovir and emtricitabine. Given that tenofovir monophosphate 341 
and emtricitabine diphosphate were not measured this helped limit problems with 342 
identifiability of model parameters. A similar model structure has recently been used to 343 
describe tenofovir and TFV-DP in healthy female volunteers (20). An indirect response 344 
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model has previously been used to describe plasma tenofovir and IC TFV-DP in HIV patients 345 
(9); however this model was not supported by our data. A simulation study reported by 346 
Madrasi et al., investigated a mechanistic model for tenofovir focusing more on describing 347 
saturable uptake and metabolism in PBMCs using literature values (11). Despite the 348 
simplistic nature of the model used for the current analysis, it performed well for both drugs 349 
and parameters generally agreed with the literature, but could be updated is further data 350 
became available (9, 13, 21).  351 
 352 
The parameters describing the IC anabolites (k24, k40, variability in k24) were estimated using 353 
data generated from a previous study (7), but also incorporated the individual predicted 354 
plasma PK parameters determined for the present study. The plasma PK parameters drive the 355 
prediction of TFV-DP and FTC-TP in the model. Therefore, the predicted TFV-DP PK 356 
parameters were slightly higher than those reported by Jackson et al., (7) because plasma 357 
tenofovir was also higher. Unsurprisingly, FTC-TP parameters were similar between studies 358 
given the agreement in plasma PK parameters. A limitation of the modelling is that external 359 
datasets are required to further evaluate the models; however it is noteworthy that the TFV-360 
DP and FTC-TP predictions are within ranges previously reported, including the PrEP 361 
population for TFV-DP (15, 20, 22). 362 
 363 
Evaluation of antiretroviral PK forgiveness and persistence within physiological 364 
compartments is also important for methods of HIV prevention, such as PrEP. Favourable PK 365 
characteristics, including prolonged elimination half-lives are beneficial for PrEP agents 366 
allowing for once daily or less frequent dosing in order to aid adherence. Based on outcomes 367 
reported from the iPrEx and Partners PrEP trials, Truvada® (tenofovir/emtricitabine) was 368 
approved as a PrEP regimen in the US (23, 24). A long acting, parenteral formulation of 369 
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rilpivirine is under development and investigations have begun to determine its suitability as 370 
a PrEP compound. Single dose rilpivirine PK in plasma and male (600 mg) and female (300, 371 
600, 1200 mg) genital tracts were assessed and shown to persist up to 84 days. The effect of 372 
rilpivirine concentrations in female genital tract fluid on HIV replication was also explored 373 
ex-vivo (5). Studies to further evaluate long acting rilpivirine as PrEP are planned 374 
[ClinicalTrials.gov Identifier: NCT02165202 (25)] or ongoing [ClinicalTrials.gov Identifier: 375 
NCT01656018 (26, 27)]. Furthermore, rilpivirine oral formulation (with or without tenofovir 376 
and emtricitabine) may be used in the context of PrEP for short periods of time (e.g. as an 377 
oral lead in dose for safety reasons or as an alternative to long acting PrEP), therefore 378 
knowledge of drug exposures after stopping drug and PK forgiveness may help to plan for 379 
this eventuality. 380 
 381 
Interpretation of these data is limited by the lack of fully validated target concentrations at 382 
which virological suppression (or prevention) occurs for rilpivirine and IC TFV-DP and 383 
FTC-TP. Therefore, the time at which virological control could be lost (or transmission 384 
occurs) or how long a dose could be delayed was not attainable. Using PK data from iPrEx, 385 
an IC TFV-DP concentration of 16 fmol/106 viable cells was associated with 90% HIV risk 386 
reduction (15). This target was also applied to data obtained from the Cell-PrEP study which 387 
investigated the achievement and maintenance of protective concentrations of 388 
tenofovir/emtricitabine in uninfected men who have sex with men. After stopping drug at day 389 
30, 80% and 48% of individuals were above this concentration at 2 and 7 days post drug 390 
cessation, respectively (28). In comparison, predicted TFV-DP from the present study were 391 
≥16 fmol/106 cells in 94% and 72% of volunteers, 2 and 7 days after stopping drug. 392 
 393 
17 
 
As this study evaluated drug PK after stopping treatment it could not be conducted in HIV-394 
infected patients and assessment of viral load after treatment interruption could not be 395 
performed. Translation from the present findings requires further study in patient populations 396 
where pharmacodynamic endpoints can be investigated given that PK between HIV-infected 397 
and healthy individuals may differ (17). Although, this study contributes significantly to our 398 
understanding of drug behaviour when therapy is stopped and the long elimination half-lives 399 
determined for all three drugs is encouraging.     400 
 401 
Adherence to antiretroviral therapy should be promoted in order to maintain optimal 402 
virological control, however, persisting plasma PK of tenofovir, emtricitabine and rilpivirine 403 
and IC TFV-DP and FTC-TP demonstrated by this study may provide a potentially forgiving, 404 
coformulated regimen for individuals that may miss or delay an occasional dose, as well as a 405 
prospective PrEP candidate.  406 
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Figure Legends 543 
 544 
FIG 1 Geometric mean plasma (A) tenofovir, (B) emtricitabine and (C) rilpivirine 545 
concentrations over 216 hours following drug intake cessation in healthy volunteers (n=18) 546 
 547 
FIG 2 Individual predicted intracellular (A) tenofovir diphosphate and (B) emtricitabine 548 
triphosphate concentrations over 168 hours following drug intake cessation in healthy 549 
volunteers on a log-linear scale (n=18; individual concentration-time profiles generated by 550 
modelling and simulation). The bold line represents the geometric mean concentration-time 551 
profile 552 
Table 1 Summary of plasma tenofovir, emtricitabine, rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate 
pharmacokinetic parameters obtained following drug intake cessation (n=18). Data presented as geometric mean (90% CI) 
 
 Plasma 
Parameter Units Tenofovir Emtricitabine Rilpivirine 
AUC0-24 
CV% 
ng.h/mL 
 
2573 (2342-3208) 
40 
8537 (7860-11955) 
53 
2116 (1929-2527) 
34 
AUC0-last 
CV% 
ng.h/mL 
 
4249 (3860-5325) 
41 
11126 (10169-15075) 
50 
7271 (6635-8761) 
36 
Cmax 
CV% 
ng/mL 
 
227 (208-280) 
38 
1260 (1148-1925) 
65 
139 (128-168) 
35 
C24 
CV% 
ng/mL 
 
53.3 (48.8-71.1) 
48 
64.7 (58.2-97.3) 
65 
76.3 (68.7-94.8) 
41 
TE half-life 
CV% 
h 
 
30.7 (27.2-39.7) 
48 
40.5 (35.8-53.5) 
51 
47.2 (41.3-59.3) 
46 
 Intracellular 
Parametera Units Tenofovir diphosphate Units Emtricitabine triphosphate 
AUC0-24 
CV% 
fmol.h/106 cells 
 
1456 (1302-2193) 
66 
pmol.h/106 cells 
 
87.8 (79.2-150) 
80 
AUC0-168 
CV% 
fmol.h/106 cells 
 
7495 (6792-11486) 
66 
pmol.h/106 cells 
 
273 (252-440) 
70 
Cmax 
CV% 
fmol/106 cells 
 
92.2 (83.8-135) 
60 
pmol/106 cells 
 
6.15 (5.73-10.5) 
75 
C24 
CV% 
fmol/106 cells 
 
54.0 (48.2-87.9) 
75 
pmol/106 cells 
 
3.07 (2.88-5.63) 
83 
AUC0-24, AUC0-168: area under the curve over 24 hours or 168 hours post-dose; AUC0-last: area under the curve to the last measureable 
concentration within 216 hours (0-216 for plasma rilpivirine); Cmax: maximum concentration; C24: concentration 24 hours post-dose; TE half-
life: terminal elimination half-life to the last measureable concentration within 216 hours (0-216 for plasma rilpivirine) 
a Parameters determined by non-compartmental analysis using concentration-time profiles generated by means of modelling and simulation 
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FIG 1 Geometric mean plasma (A) tenofovir, (B) emtricitabine and (C) rilpivirine 
concentrations over 216 hours following drug intake cessation in healthy volunteers (n=18) 
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FIG 2 Individual predicted intracellular (A) tenofovir diphosphate and (B) emtricitabine 
triphosphate concentrations over 168 hours following drug intake cessation in healthy 
volunteers on a log-linear scale (n=18; individual concentration-time profiles generated by 
modelling and simulation). The bold line represents the geometric mean concentration-time 
profile 
 
